Menu
Kinetic Oscillation Stimulation, K.O.S., was originally developed to treat chronic rhinitis – what is commonly called nasal congestion. During the years that K.O.S. was tested and studied, several patients reported that their migraine symptoms ceased or subsided after being treated for rhinitis. This is now the subject of a study which is expected to be completed during 2022.
The treatment is performed by inserting a balloon catheter into one nostril at a time, inflating the balloon and making it vibrate at a specific frequency. This goes on for ten minutes per nostril.
The clinical benefit of using K.O.S to treat chronic rhinitis is proven and well-supported in research. The treatment is in use in several countries, and the number of clinics using K.O.S. is increasing. A comprehensive study is currently being conducted at 13 clinics and with approximately 300 patients. An interim analysis of the rhinitis study was performed, during the fall of 2020, which indicated a too low probability to reach a conclusive result. Hence, the inclusion of further patients was halted for ethical and cost reasons. Howver, the study contiues with follow-up for 12 months of the patients already enrolled.
In 2020, the University of Amsterdam published a study which analyzed data from an older study, carried out in 2013-2014, and which concluded that K.O.S. treatment has a significantly better effect on patients than placebo treatment. This confirms our view that the rhinitis market for K.O.S. has great potential.
When it comes to migraine, the research situation is very promising. The interim analysis that was conducted of the ongoing study during spring 2019 gave clearly positive indications. The interim analysis recommended that the study should continue with the current number of patients. We interpret that as a clear signal that the study is properly designed and that it is likely to achieve the desired result. Chordate was subsequently awarded a CE mark based on data from the interim analysis. Many leading neurologists are following the research with great interest. The study is expected to start treatment of the last patients during the first quarter of 2022.
K.O.S. is completely pain free and can easily be performed by a nurse or doctor after a medical examination. The patient may experience some discomfort during the first few minutes, mostly due to the unusual feeling of having something inserted into the nose – but no pain.
The effect of the rhinitis treatment is felt within a few hours. The effect also increases and is usually fully felt one to two days after treatment. Normally, two initial treatments are performed at one-month intervals, after which one to two treatments per year is usually sufficient for patients with chronic rhinitis to experience noticeable improvement.
For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical’s share is listed on the Nasdaq First North Growth Market (ticker: CMH).